Business

Mass. Movers

Biogen Idec gains on new MS drug’s sales

Biogen targets autoimmune and neurodegenerative disorders and hemophilia.
Suzanne Kreiter/Globe Staff/File
Biogen targets autoimmune and neurodegenerative disorders and hemophilia.

Biogen Idec Inc. shares climbed 4.9 percent to a record $223.98 before closing at $223.61, up
­4.7­ percent. The Weston company’s new multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis and Sanofi, Bloomberg News reported, suggesting the treatment may beat sales estimates for the year. Total­ prescriptions more than doubled during the third week of the launch to 730 from 332 the previous week, according to Wells Fargo & Co.

Advertisement